Abstract
Despite a dearth of activating driver mutations in head and neck squamous cell carcinoma (HNSCC), aberrant activation of the oncogenes, epidermal growth factor receptor (EGFR), and c-Met is near-universal in human papillomavirus (HPV)-negative disease. Although EGFR activation drove the successful development of the anti-EGFR monoclonal antibody cetuximab in HNSCC, no c-Met-targeting therapy has gained regulatory approval. Inhibition of the c-Met pathway may subvert oncogenesis within the tumor-intrinsic compartment, blocking tumoral proliferation, invasion, migration, and metastasis, or the tumor-extrinsic compartment, modulating the immunosuppressive tumor microenvironment. This review discusses the rationale and current drug development strategies for targeting c-Met or its exclusive ligand hepatocyte growth factor (HGF) in HNSCC.
Original language | English (US) |
---|---|
Pages (from-to) | 346-353 |
Number of pages | 8 |
Journal | Cancer Journal |
Volume | 28 |
Issue number | 5 |
DOIs | |
State | Published - Sep 1 2022 |
Externally published | Yes |
Keywords
- HGF
- c-Met
- head and neck squamous cell carcinoma
ASJC Scopus subject areas
- Oncology
- Cancer Research